PHN-020 / Pheon Therap - LARVOL DELTA

Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline (PRNewswire) - "Pheon Therapeutics...today announces the completion of a $120m Series B financing to fund the development of its pipeline of differentiated ADCs....The new financing will be used to further advance Pheon's differentiated ADC pipeline through clinical proof of concept. The first three assets are aimed at an undisclosed novel target which is highly overexpressed in a wide range of solid tumors. The first program has demonstrated an unprecedented preclinical therapeutic index while utilizing a DAR8 Topoisomerase-1 inhibitor linker-payload, whereas the next two ADCs utilize other linker-payload technologies to mine the broad potential of this target. The company expects to start its first Phase 1 clinical trial in 2024 and rapidly advance towards dose expansion cohorts. The capital will also enable the expansion of Pheon's suite of in-house technology platforms to generate optimized ADC constructs."

Financing • New P1 trial • Oncology • Solid Tumor